Late Stage Chronic Kidney Disease Therapeutics Market By 2022 to 2032: Patient-Centric Care Models

BySanket Badgujar
Late Stage Chronic Kidney Disease Therapeutics Market

The global late stage chronic kidney disease therapeutics market has experienced a significant upsurge in recent years, propelled by the rising prevalence of CKD worldwide. According to recent market research, the late stage CKD therapeutics market was valued at approximately USD 4.7 Billion in 2019. It is projected to exceed USD 11.1 Billion by 2027, demonstrating a remarkable Compound Annual Growth Rate (CAGR) of around 11.6% during the forecast period from 2022 to 2032.

Chronic kidney disease has emerged as a critical public health concern globally, characterized by its high morbidity and mortality rates. Factors such as diabetes mellitus, hypertension, obesity, and aging are recognized as primary contributors to this fatal condition.

Snatch Your Sample Report Revealing the Most Recent Market Trends

The escalating demand for effective therapeutics to manage and treat late stage CKD is driving innovation and investment in the market. With an increasing number of patients being diagnosed with CKD, the need for advanced treatment options is more pressing than ever.

As the market continues to expand, key players in the healthcare and pharmaceutical industries are focusing on developing and delivering cutting-edge therapies to improve patient outcomes and quality of life. The future of CKD treatment looks promising, with ongoing research and development paving the way for more effective and accessible therapeutic solutions.

Late Stage Chronic Kidney Disease Therapeutics Market Poised for Significant Growth Driven by Rising Prevalence and Innovation:

The global market for late-stage chronic kidney disease (CKD) therapeutics is anticipated to experience significant growth in the coming years, fueled by several key factors.

This highlights the major drivers propelling this market expansion:

Rising Global Disease Burden Creates Market Demand:

A critical factor driving market growth is the alarming rise in chronic kidney disease prevalence worldwide. According to a Lancet report, an estimated 700 million people were affected by CKD in 2017, with projections indicating a further surge in the coming years. This increasing disease burden translates to a growing demand for effective treatment options, particularly for patients in late stages.

Market Bolstered by Innovation and Expanding Awareness:

The introduction of novel and advanced late-stage CKD therapeutics is another key growth driver. These innovative solutions offer improved treatment outcomes and address unmet needs in patient care. Additionally, growing awareness among patients and healthcare professionals regarding the benefits of these late-stage therapies is significantly impacting market dynamics.

Favorable Reimbursement Policies and Limited Dialysis Access Create Opportunities:

The establishment of favorable reimbursement policies for CKD treatment by government bodies and healthcare institutions is creating a supportive environment for market expansion. This, coupled with limited access to renal replacement therapy (RRT) and dialysis, particularly in developing nations, paves the way for increased adoption of late-stage CKD therapeutics as a viable treatment alternative.

A Promising Future for Late-Stage CKD Therapeutics:

The confluence of these factors – rising disease prevalence, innovative treatment options, growing awareness, and supportive policies – paints a promising picture for the late-stage chronic kidney disease therapeutics market. This market is well-positioned for robust growth in the foreseeable future.

Key Companies Profiled:

  • Amgen
  • Deltanoid
  • AbbVie
  • Sanofi
  • Ardelyx
  • AstraZeneca
  • Kyowa Hakko Kirin
  • Genzyme, Keryx
  • Spectrum
  • Mitsubishi Tanabe
  • OPKO Health
  • Relypsa
  • Shield Therapeutics
  • Shire
  • Vifor
  • ZS Pharma

Key Segments Profiled in the Late Stage Chronic Kidney Disease Therapeutics Industry Survey:

By Product Type:

  • Calcimimetics
  • Sensipar (cinacalcet hydrochloride)
  • Vitamin D Sterols
  • Nutritional/Native Vitam:in D
  • Vitamin D Receptor Agonists
  • Phosphate Binders
  • Calcium-Based Phosphate Binders
  • Aluminum-Containing Phosphate Binders
  • Magnesium-Containing Phosphate Binders
  • Renvela/Renagel
  • Fosrenol (lanthanum carbonate)
  • Velphoro (sucroferric oxyhydroxide)
  • Auryxia (ferric citrate)
  • Potassium Binders
  • Resins
  • Veltassa (patiromer sorbitex calcium)

By Indication:

  • Hyperparathyroidism
  • Hyperphosphatemia
  • Hyperkalemia

By End Users:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Mail Order Pharmacy

By Region:

  • North America
  • Latin America
  • Western Europe
  • Eastern Europe
  • APEJ
  • Japan
  • Middle East & Africa